Nuwellis (NASDAQ:NUWE – Get Rating) will be issuing its quarterly earnings data before the market opens on Tuesday, May 10th. Parties interested in registering for the company’s conference call can do so using this link.
Nuwellis (NASDAQ:NUWE – Get Rating) last posted its earnings results on Tuesday, March 1st. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.07. Nuwellis had a negative return on equity of 69.75% and a negative net margin of 247.17%. During the same quarter in the prior year, the firm posted ($1.13) earnings per share. On average, analysts expect Nuwellis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Nuwellis stock opened at $0.74 on Tuesday. The company has a market cap of $7.40 million, a P/E ratio of -0.24 and a beta of 0.88. Nuwellis has a one year low of $0.74 and a one year high of $5.39. The stock’s 50 day moving average is $0.95.
Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new stake in Nuwellis during the 2nd quarter valued at $45,000. Geode Capital Management LLC increased its holdings in Nuwellis by 17.6% during the 3rd quarter. Geode Capital Management LLC now owns 43,819 shares of the company’s stock valued at $96,000 after purchasing an additional 6,561 shares in the last quarter. Millennium Management LLC acquired a new stake in Nuwellis during the 2nd quarter valued at $112,000. Finally, Renaissance Technologies LLC increased its stake in shares of Nuwellis by 15.8% in the 4th quarter. Renaissance Technologies LLC now owns 205,600 shares of the company’s stock valued at $234,000 after buying an additional 28,003 shares during the period. 18.18% of the stock is owned by hedge funds and other institutional investors.
Nuwellis Company Profile (Get Rating)
Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.
- Get a free copy of the StockNews.com research report on Nuwellis (NUWE)
- GitLab Stock is Trying to Put in a Bottom Here
- It’s Time to Book an Appointment for Teladoc Stock
- Saia Growth Accelerates But It May Not Matter
- onsemi Is A Deep-Value In The Chip Sector
- Is The FOMC About To Spark A Massive Stock Market Correction?
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.